Calendario›REGN›Honey-B
Honey-B
Ensayo de REGENERON PHARMACEUTICALS, INC. en Hemophilia B (del registro, en inglés).
- Fase
- no aplica
- Estado
- En marcha, sin reclutar
- Participantes
- 11
- Centros
- 17
- Fin del objetivo primario
- nov 2026
Título oficial en el registro (en inglés): A Trial That Evaluates Disease Characteristics in Hemophilia B Adult Male Participants Receiving Prophylaxis With Standard of Care Factor IX Protein (FIX) Replacement Therapy
Qué significa cada fase y cada estado.
Estudio observacional. Comenzó en ene 2024.
De principio a fin
Desde que lo vigilamos, su lectura se ha retrasado 3 meses en total.
- Empieza el ensayo (ene 2024)
- Mueve la lectura: ago 2026 → nov 2026 (+3 meses) · visto el 10 nov 2026
- Lectura de resultados nov 2026 (prevista)
- Hoy
Los cambios los anota PivotalWire desde agosto de 2026; lo anterior no lo tenemos. El historial completo, versión a versión, está en ClinicalTrials.gov.
Lo que ha cambiado
Movimientos registrados desde que PivotalWire vigila este ensayo. Un retraso no se anuncia: se ve comparando, y esto es la comparación ya hecha.
| Visto | Qué se mueve | Cambio |
|---|---|---|
| 10 nov 2026 | Lectura de resultados | ago 2026 → nov 2026 |
Qué mide
Annualized bleeding rate (ABR) (At least 26 Weeks Up to 96 weeks) (del registro, en inglés)
Qué se prueba
El estudio reúne al menos 6 meses de información sobre episodios de sangrado en participantes que siguen con su tratamiento habitual con FIX.
Lo que dice el documentoto gather at least 6 months of information on bleeding events for each individual participant while they continue to use their usual FIX replacement therapy.
Traducción automática (claude-haiku-5-5). Lo comprobado es la cita: está literal en el documento y sus cifras cuadran con las de la frase. Todavía no la ha leído una persona.
Cómo lo describe el promotor
En el documentoEn inglés, del registroThis study is focused on males who have Hemophilia B and who need regular preventive treatment with factor IX protein (FIX) replacement therapy to prevent and also to control their bleeding events. The aim of the study is to gather at least 6 months of information on bleeding events for each individual participant while they continue to use their usual FIX replacement therapy. There is no experimental treatment being tested in this study. The study is informational, and part of a larger program to understand and treat Hemophilia B with a potential experimental new therapy in the future. There is no obligation to agree to taking part in this future study. The study is looking to answer several other research questions to help understand each participant's individual disease characteristics, including: * How often to use FIX replacement therapy, both on a regular basis (prophylaxis) and as needed to treat bleeding events * Measurement of FIX activity (factor IX is a clotting factor) by different laboratories using different types of tests in Hemophilia B participants * Possible complications from the FIX replacement therapy the patient receives (usual standard of care will continue to be used) * How quality of life is affected by Hemophilia B * How joint health is affected by Hemophilia B * How often the participant visits the emergency room, urgent care center, physician's office, hospital, or has a telemedicine visit as a result of bleeding events * Whether the body makes antibodies (a protein produced by the body's immune system) against the FIX replacement therapy you receive, which could make the drug less effective or could lead to side effects
Más ensayos de REGN
| Ensayo | Fase | Estado | Lectura de resultados |
|---|---|---|---|
| cemiplimab | Fase 2 | En marcha, sin reclutar | mar 2025 (real) |
| Pozelimab + Cemdisiran · NIMBLE | Fase 3 | En marcha, sin reclutar | jul 2025 (real) |
| Garetosmab · OPTIMA | Fase 3 | En marcha, sin reclutar | jul 2025 (real) |
| Aflibercept 8 mg · ELARA | Fase 3 | En marcha, sin reclutar | ago 2025 (real) |
| Dupilumab · ENGAGE | Fase 2 | En marcha, sin reclutar | feb 2026 (real) |
| Fianlimab | Fase 3 | En marcha, sin reclutar | mar 2026 (real) |
Todos los de REGN, en su ficha.
Ficha completa en ClinicalTrials.gov (NCT05568459), actualizada en nov 2026.